Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced four poster presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held November 1-5, 2023, in San Diego, CA.
- “This continues to be a definitive year for Senti with multiple presentations across multiple medical and scientific venues,” said Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio.
- “The four posters at this year’s SITC meeting highlight the breadth and modularity of our platform.
- Senti’s Bio proprietary Logic Gating can help design cell therapies that address more tumor types by increasing the therapeutic window.
- Senti Bio has developed a robust platform for high-throughput promoter discovery that leverages both pooled library screening and automated end-to-end clonal screening.